Vitamin-based PD-1 pathway blockade for Human cancer therapy: Cholecalciferol, a form of Vitamin-D3, decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 17 June, 2017, 12.23 am

Music therapy for Stroke: Music attenuates hippocampal neurons injury, augments regenerative neurogenesis after Ischemic Stroke, and ameliorates stroke damage and neurological deficits via up regulation of its target genes BDNF and NAMPT., 17/June/2017, 12.20
June 16, 2017
Natural product-derived therapy for brain tumor and oesophageal squamous cell carcinoma: Rhamnetin, one of the main components of Cloves, inhibits the expression of Integrin a7 (ITGA7), impairs laminin-induced/FAK mediated signalling, inhibits the proliferation of glioblastoma and oesophageal squamous cell carcinoma stem cells, suppresses tumor cell migration, reduces metastasis and prolongs survival via down regulation of its target gene, 17/June/2017, 10.34 pm
June 17, 2017
Show all

Introduction:What they say

A recent study from Cell Signalling Section, Division of Immunology, Department of Pathology, Tennis Court Road, University of Cambridge, Cambridge CB2 1QP, UK shows that “Glycogen Synthase Kinase 3 Inactivation Drives T-bet-Mediated Downregulation of Co-receptor PD-1 to Enhance CD8(+) Cytolytic T Cell Responses.” This study was published in the 16 February 2016 issue of Immunity (one of the best journals in Immunology with an impact factor of 20+) by Prof Rudd CE, Taylor A and others.


What we say

price-quote

On the foundation of this interesting finding, Dr L Boominathan PhD, Director-cum-chief Scientist of GBMD, reports that: Vitamin-based PD-1 pathway blockade for Human cancer therapy: Cholecalciferol, a form of Vitamin-D3,  decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene


What is known?

It has recently been shown that blocking PD-1 with antibodies one could make tumors shrink. This work, relating to Cancer immunotherapy, has been chosen as Science’s breakthrough of the year.


Research Findings

This study suggests a vitamin-based Human cancer therapy.

cholecalciferol க்கான பட முடிவு

Figure 1. Cholecalciferol. Cholecalciferol, enhances cytolytic function of Cytotoxic T-lymphocytes, augments anti-tumor activity, and inhibits metastatic cancer progression via downregulation of Glycogen synthase kinase-3β and PD-1

Cholecalciferol (a form of Vitamin-D), by increasing the expression of its target gene, it may suppress the expression of Glycogen synthase kinase 3-β. Thereby, it may: (a) increase transcription factor T-bet expression; (b) inhibit co-inhibitory receptor PD-1 expression;  (c) increase CD8(+) cytotoxic T lymphocyte function; (d) augment anti-tumor activity; & (e) inhibit metastatic cancer progression.


Therapeutic opportunity

Thus, pharmacological formulations encompassing “Cholecalciferol or its analogues, either alone or in combination with other drugs” may be used to inhibit the progression of tumors.


Details of the research findings:

Idea Proposed/Formulated (with experimental evidence) by: Dr L Boominathan Ph.D.

Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/

Amount: $500#

Undisclosed information: How Cholecalciferol suppresses the expression of PD-1 and augments anti-tumor immunity

# Research cooperation


References:

Citation: Boominathan, L., Vitamin-based PD-1 pathway blockade for Human cancer therapy: Cholecalciferol, a form of Vitamin-D3,  decreases the expression of Glycogen synthase kinase-3β, increases transcription factor T-bet expression, decreases the abundance of co-inhibitory receptor PD-1 on the cell surface of Cytotoxic-T-cells, increases cytotoxic T lymphocyte function and augments anti-tumor activity, via up-regulation of its target gene, 17 June, 2017, 12.23 am, Genome-2-Bio-Medicine Discovery center (GBMD), http://genomediscovery.org

Web: http://genomediscovery.org or http://newbioideas.com

Courtesy: When you cite drop us a line at info@genomediscovery.org

Comments are closed.